Nutrition68163 384.390

The Journal of NutritionNutrient Requirements and Optimal Nutrition Intake of Fish Oil, Oleic Acid, Folic Acid, andVitamins B-6 and E for 1 Year Decreases PlasmaC-Reactive Protein and Reduces Coronary HeartDisease Risk Factors in Male Patients in aCardiac Rehabilitation Program1 Juan Jesu´s Carrero,2 Juristo Fonolla´,3 Jose´ Luis Marti,4 Jesu´s Jime´nez,3 Julio J. Boza,3and Eduardo Lo´pez-Huertas3* 2Department of Biochemistry and Molecular Biology, University of Granada, Spain; 3Department of Human Nutrition, Puleva Biotech, Granada, Spain; and 4Service of Cardiology, University ‘‘San Cecilio’’ Hospital, Granada, Spain Certain nutrients have been shown to be effective in preventing coronary heart disease. We hypothesized that a daily intake of low amounts of a number of these nutrients would exert beneficial effects on risk factors and clinical variables in patients that suffered from myocardial infarction (MI) and were following a cardiac rehabilitation program. Forty male MI patients were randomly allocated into 2 groups. The supplemented group consumed 500 mL/d of a fortified dairy product containing eicosapentaenoic acid, docosahexaenoic acid, oleic acid, folic acid, and vitamins A, B-6, D, and E. The control group consumed 500 mL/d of semi-skimmed milk with added vitamins A and D. The patients received supervised exercise training, lifestyle and dietary recommendations, and they were instructed to consume the products in addition to their regular diet. Blood extractions and clinical examinations were performed after 0, 3, 6, 9, and 12 mo. Plasma concentrations of eicosapentaenoic acid, docosahexaenoic acid, oleic acid, folic acid, vitamin B-6, and vitamin E increased after supplementation (P , 0.05). Plasma total and LDL-cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein concentrations decreased in the supplemented group (P , 0.05), and plasma total homocysteine decreased in both groups. There were no changes in heart rate, blood pressure, or cardiac electrocardiographic parameters in either group.
Therapeutic lifestyle changes, effected through a CR program comprising regular exercise and the intake of a combination of dietary nutrients, reduced a variety of risk factors in MI patients, which supports the rationale for nutritional programs in the secondary prevention of coronary heart disease.
who have received a diagnosis of MI. The overall objectives of Acute myocardial infarction (MI),5 a manifestation of athero- CR are to optimize patients’ functioning by decreasing disabil- sclerosis caused by the occlusion of coronary arteries, is the ities resulting from coronary heart disease (CHD), enhancing the leading cause of death for both men and women all over the quality of life, and minimizing the risk of recurrent cardiac world. It is also a major cause of physical disability, particularly events and hospitalization (2,3). Comprehensive rehabilitation in the rapidly growing population of elderly persons (1). Cardiac programs usually combine supervised exercise training and be- rehabilitation (CR) programs are recommended for patients havioral changes (smoking cessation, control of excess weight,and increased physical activity) with lifestyle and nutritionalcounseling, thus aiming to reduce the cardiovascular (CV) riskfactors that are generally increased in these patients (4).
1 Supported in part by a PhD education grant from the University of Granada Cholesterol-lowering therapies remain the main strategies (J.J.C.). Dairy products were supplied by Puleva Food S.L., Granada, Spain.
5 for primary and secondary prevention of CHD (4). Numerous Abbreviations used: AA, arachidonic acid; ApoB, apolipoprotein B; C, control studies report a direct relation between levels of total or LDL- group; CHD, coronary heart disease; CR, cardiac rehabilitation; CV, cardiovas-cular; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HDL-C, HDL cholesterol (LDL-C) and the rate of CHD in healthy individuals cholesterol; hs-CRP, high-sensitivity C-reactive protein LDL-C, LDL cholesterol; and in people with established CHD (5–8). Moreover, several MI, myocardial infarction; S, supplemented group; sICAM-1, soluble intercellular prospective studies indicate that plasma levels of high-sensitivity cell adhesion molecule 1; sVCAM-1, soluble vascular cell adhesion molecule 1; C-reactive protein (hs-CRP), a marker of systemic inflammation, TC, total cholesterol; TG, triacylglycerols; tHcy, total plasma homocysteine.
* To whom correspondence should be addressed. E-mail: [email protected] are a strong independent predictor for the risk of future CV events among individuals, including MI patients (9–11).
0022-3166/07 $8.00 ª 2007 American Society for Nutrition.
Manuscript received 12 October 2006. Initial review completed 13 October 2006. Revision accepted 9 November 2006.
There is a wealth of evidence regarding the benefits produced or during the cardiac rehabilitation program; 2) endocrine or metabolic by changing lifestyle habits, dietary patterns, and nutrients in the disturbances; 3) blood concentrations of LDL-C .3.4 mmol/L, or HDL-C primary and secondary prevention of CHD. Among those, a ,1 mmol/L, or triacylglycerols .1.7 mmol/L; 4) using a prescription of Mediterranean dietary pattern, characterized by a high intake of lipid lowering drugs (statins); 5) liver insufficiency; 6) residence outside olive oil (rich in oleic acid and antioxidants), fish [rich in (n-3) the recruitment area of the study; 7) unable to come to the CR unit;8) taking fish oil supplements.
long-chain PUFA], vegetables and fruits (rich in folic acid andother vitamins), has been associated with a lower CHD inci- Study protocol and diets. We carried out a longitudinal, randomized, dence and total mortality (12–14).
controlled, double-blind intervention study to investigate the effects of a In this sense, the AHA recommends to MI patients a daily nutritional supplement in markers of CHD of a group of men following a intake of 1 g of eicosapentaenoic acid (EPA) and docosahex- cardiac rehabilitation program after an episode of MI.
aenoic acid (DHA) from fish or fish oils (15). Dietary intakes of From June to October 2003, 71 possible candidates were recruited; folate and/or vitamin B-6 have been described as the main 27 of them did not fulfill the inclusion criteria because of residence nutrients responsible for lowering hyperhomocysteinemia, outside the metropolitan area of Granada (n ¼ 7), taking prescription which is considered an independent risk factor for CVD (16).
statins 1 mo before the time of the inclusion due to high blood LDL-C Consequently, European Recommended Dietary Allowances for concentration (n ¼ 4), clinical history of stroke or peripheral vasculardisease (n ¼ 3), or a lack of willingness to participate (n ¼ 13). The these vitamins have been well established (17). Evidence has remaining candidates were randomly assigned to 2 intervention groups been recently gathered by the latest WHO report, which rec- of 20 subjects each, using a table of random numbers (Fig. 1).
ommends 1) regular fish consumption to provide ;200–500 mg The patients received tailor-made exercise instructions and attended of EPA 1 DHA/wk, 2) a replacement of saturated fat by the CR unit twice/wk for exercise classes. They also were encouraged to monounsaturated fat (to increase the oleic acid intake), and 3) exercise on their own every day (walk for 30 min to 1 h). Participating an increase in the consumption of fruit and vegetables to achieve subjects gave their written consent. The protocol was approved by the proper antioxidant and folate status (18). Despite the recom- Ethical Committee of S. Cecilio University Hospital and it was mendations, modern Western societies tend to include little fish, conducted in accordance with the Helsinki Declaration. The study fruit, and vegetables in their diets (18). In addition, whereas CR lasted 12 mo, from November 2003 to December 2004. Details of the programs emphasize the adherence to healthy dietary patterns, drugs prescribed to the subjects were recorded at baseline (Table 1).
The supplement (S) group (n ¼ 20) was supplied with 500 mL/d of a their implementation is often unsuccessful and usually involves fortified dairy product (Puleva Omega3, Puleva Food) containing the An effective approach to increasing the intake of healthy dietary nutrients that may lead to a decrease of CHD risk is theenrichment of foods that are regularly consumed by the majority of the population (20–24). We recently conducted a nutritionalintervention with this nutritional approach in patients sufferingfrom peripheral vascular disease, showing improvements inclinical outcomes while undertaking reductions in a variety ofrisk factors (23). With MI being the most frequent manifestationof CV disease, we hypothesized that the inclusion of a sup-plement in the daily diet of MI patients would help improvenutritional status and risk profile in the context of a CR pro-gram, and we carried out a longitudinal, controlled, random-ized, double-blind, 12-mo intervention with a dairy productcontaining low amounts of EPA and DHA, oleic acid, folic acid,and vitamins A, D, E, and B-6.
Subject recruitment. Subject recruitment was conducted at the CardiacRehabilitation Unit of the University Hospital of Granada (Spain).
Hospital records and medical history of the patients were consultedbefore their inclusion in the study. All male patients diagnosed with atleast 1 episode of acute MI and followed and successfully completedphase II of the CR program, and patients already on phase III, werecandidates for inclusion in the study. Phase II of the CR programtypically started after hospital discharge and usually lasted for 3 mo.
During this phase, the patients were assessed for cardiovascular risk andreceived lifestyle and nutritional counseling, supervised exercise training,drug therapy, and psychological support. In phase III, the patients werereferred to their medical centers for follow-up, where general practi-tioners supervised the CR of the patients in accordance with theguidelines received from the CR unit (25). For this study, the patientsincluded in the study were asked to visit the CR unit twice/wk for the12-mo duration of the study. Patients were not admitted to the study ifany of the following criteria were present: 1) at high-risk after hospitaldischarge (New York Heart Association class III and IV), low functionalcapacity, ventricular arrhythmia, severe valvular disease, severe heartfailure, or presenting with additional CV events during the hospital stay Baseline characteristics of the participating subjects1 program-Phase II, and also 2 wk before the 1st delivery of the study’sdairy beverages (in phase III), the subjects and their partners attended a dietary counseling session on general aspects of food composition, foodprocessing, adequate portions, the effects of alcohol consumption, and the beneficial effects of the Mediterranean diet. Subjects received a leaflet with information about the CV benefits produced by fish consumption and were also advised to increase the consumption of fruit, legumes, and vegetables to ensure adequate intake of fiber and vitamins. They wereadvised not to eat fast food or precooked meals and to avoid smoky places or to stop smoking. Dietary intake was assessed at baseline and again at the end of the study with a 7-d self-administered food-frequency questionnaire, following instructions from the principal investigator.
Spanish food composition tables were used to estimate dietary intake Blood extraction and clinical examination. The patients were interviewed in the hospital at the beginning of the study (T0) and after3, 6, 9, and 12 mo (T 3, T6, T9, and T12). At every visit, after an overnight Data are presented as means 6 SEM or n (%); n ¼ 20/group. * Different from C, fast of at least 10 h, blood samples (30 mL) were collected by venipuncture into vacutainer tubes containing EDTA. Samples werekept on ice before centrifugation at 1700 3 g for 15 min at 4°C to obtain plasma. To ensure analytical consistency, plasma samples T0 –T12 from following nutrients: EPA, DHA (from fish oils), oleic acid, folic acid, and each subject were processed at the same time and analyzed in 1 batch.
vitamins A, B-6, D, and E. The dairy supplement was prepared by adding The subjects also received a complete clinical examination, including a mixture of fish and vegetable oils to skimmed milk, yielding a product an anamnesis. Blood pressure and heart rate were determined. Electro- containing a total fat comparable to that of standard semi-skimmed milk cardiogram tests were performed and recorded at the times of the study.
(19 g/L), but with a different fatty acid profile. Folic acid and vitamins A, P-wave, QRS complex, and T-wave abnormalities were measured and B-6, D, and E were also added to the final product. The control (C) group (n ¼ 20) was supplied with 500 mL/d of regular semi-skimmed milk withadded vitamins A and D (Table 2). The dairy products were produced Biochemical measurements. The plasma concentrations of triacyl- and packaged in white 500 mL Tetra Bricks by Puleva Biotech S.A., so glycerols (TG), total cholesterol (TC), and HDL cholesterol (HDL-C) that neither the patients nor the researchers would know what was were measured at the hospital central laboratory by colorimetry, using consumed. The patients were instructed to consume the dairy products, commercial kits (Biosystems). Analyses were conducted in triplicate and in addition to their regular diets, in 2 3 250 mL doses at the beginning in 1 batch, following the protocols provided by the manufacturer. Plasma and at the end of the day. The dairy products were home-delivered to the LDL-C was calculated according to the Friedewald formula (27). Plasma patients monthly. Compliance with the consumption protocol during the fatty acid profiles were determined by GLC (28). Plasma apolipoprotein intervention period was ensured and monitored by regular telephone B (ApoB) was measured using an immuno-turbidimetry test (Olympus calls and collection of the emptied containers. At the beginning of the CR Diagnostica). Plasma concentrations of total homocysteine (tHcy), vita-min E, and malondialdehyde were quantified by HPLC with fluorescencedetection (29–31, respectively). Plasma vitamin B-6 concentration wasalso measured by HPLC, using instructions from a commercial kit (Immundiagnostik). Plasma and RBC folate concentrations were mea-sured using commercial immunoassay kits (ICN Pharmaceuticals).
Soluble vascular adhesion molecule 1 (sVCAM-1) and soluble intercel-lular cell adhesion molecule 1 (sICAM-1) concentrations were measured by ELISA commercial kits (Biosource International). Hs-CRP concen- trations in plasma were quantified by an immuno-nephelometric com- mercial kit (Dade Behring). Oxidized LDL in plasma was quantifiedusing an ELISA kit (Mercodia). ApoB, hs-CRP, and the vitamins described above were measured in 1 batch at Balague´ Center Labora- Statistical analysis. The data were analyzed using SPSS software (version 12.0). Data are expressed as means 6 SEM, and differences of P , 0.05 were considered significant. Normality was assessed by the Kolmogorov-Smirnov test. Between-group comparisons at the beginning of the study were assessed by an independent t test or Mann-Whitney test for the non-Gaussian variables. The longitudinal effect of each dairy product within each group at the various time points of the study was analyzed by 1-way repeated-measures ANOVA followed by Tukey’s honestly significant difference post hoc test (within-group comparison).
Statistical differences produced by the consumption of each dairy prod- uct were analyzed using 2-way repeated-measures ANOVA. For the non- Gaussian variables, Wilcoxon and Krustal-Wallis comparisons were performed to assess differences within and between groups, respectively.
When between-group comparisons showed significant differences, an independent t test or Mann-Whitney test was applied to determine the time points at which the groups differed. The relations among increased plasma nutrients concentrations and CHD risk-factor improvement were assessed using two-tailed Pearson’s bivariate correlations.
(Table 5). Plasma tHcy concentrations at baseline were withinthe normal range (,15 mmol/L) in both study groups (32). The S Baseline characteristics of the subjects included in the groups group exhibited a within-group reduction in the plasma tHcy (Table 1) did not change from the beginning to the end of the concentration beginning at T3 that was sustained throughout the study (not shown). At entry, 50% of patients were overweight intervention, whereas the C group had only a modest reduction (BMI $25 and ,30 kg/m2) and 33% were obese ($30 kg/m2).
at T12. The vitamin E in the supplemented dairy product The dairy products used were well accepted and compliance was increased the plasma vitamin E concentration and the vitamin good. Dietary intake of nutrients did not differ between the beginning and the end of the study (not shown). None of the The plasma hs-CRP concentration at baseline was above patients included suffered further CV events during the study.
high-risk values (.3 mg/L; 32) in both study groups. In the S One patient in the S group did not finish the study due to taking group, this concentration decreased 20% at T6 and 48% at T12 a prescription of statins (n ¼ 1). The rest of the patients (Table 5). The reductions were more pronounced when the successfully completed the study (Fig. 1).
subjects with baseline values .3 mg/L were considered sepa- The amounts of oleic acid, DHA, and EPA daily supple- rately and the changes were independent of weight reduction.
mented in 500 mL of the enriched product were 5.12 g, 0.13 g, Decreases in the hs-CRP of the subjects were directly correlated and 0.2 g, respectively, whereas the semi-skimmed milk con- with the increases in plasma EPA 1 DHA (r ¼ 20.52, P ¼ 0.03) tained only 1.82 g oleic acid/500 mL and undetectable levels of and EPA alone (r ¼ 20.51; P ¼ 0.04) and tended to be correlated DHA and EPA. The plasma fatty acid profile did not change in with decreases plasma tHcy (r ¼ 0.42; P ¼ 0.08).
patients from the C group, but in the S group, consumption of The plasma concentration of sICAM-1 increased slightly in the fortified dairy product significantly increased the propor- the C group at T6 (276 6 14 mg/L; P , 0.05) and T12 (285 6 13 tions of EPA, DHA, and the decreased ratio of arachidonic acid mg/L; P , 0.05) compared with initial values (247 6 13 mg/L).
(AA) to EPA (Table 3). The plasma oleic acid level was greater in In contrast, the plasma slCAM-1 concentration tended to the S group at T6 and T12 compared with baseline, but at no time decrease (P ¼ 0.06) in the S group (from 289 6 22 at T0, to did the S and C groups differ. Plasma total saturated fatty acid 269 6 15 at T6, and 254 6 18 mg/L at T12). Other markers of levels in the C group and monounsaturated fatty acid levels in endothelial dysfunction, such as sVCAM-1, and of plasma the S group tended to increase (P ¼ 0.06). Other plasma fatty oxidizability, such as malondialdehyde, and oxidized LDL did not change in either group (data not shown). Blood pressure, The plasma TC and LDL-C concentrations decreased in the S heart rate, and results of the electrocardiogram tests did not group at T9 and T12. The TC, but not the LDL-C concentration, change in either group throughout the study (data not shown).
differed between the S and C groups at these times. The plasma HDL-C and TG concentrations did not change in either groupduring the study, whereas the plasma concentration of ApoBsignificantly decreased at T The amounts of folic acid and vitamin B-6 daily supple- We found that the inclusion of a combination of nutrients in the mented in 500 mL of enriched product were 150 mg and 1.5 mg, daily diet of a group of male MI patients following a CR respectively. Plasma vitamin B-6 and plasma and RBC folate program may improve nutritional status and reduce CHD risk concentrations increased in the S group but not in the C group factors. The way the nutrients were administered (in a beverageconsumed daily) may have contributed to the good complianceobtained with the protocol, as shown by the percentages of the Relevant plasma fatty acids in the C and S groups plasma fatty acids and plasma concentration of vitamins that at the beginning of the study (T0), after 6 mo (T6), varied in response to the nutrients supplemented, which is in agreement with similar studies (21–24). In fact, the absorptionof EPA and DHA from fish oil is improved when associated with other fats and spread out in small doses during the day (33), and the fact that milk fat is highly dispersed in very small micelles, increasing the surface of absorption of fats and lipid-soluble compounds (20), may explain the metabolic effects achieved when only small amounts were administered.
Although the prescription of the drugs, exercise, recommen- dations for healthier lifestyle, and the Mediterranean dietary pattern of the CR program resulted in the ability of C-group patients to maintain their lipid concentrations within the de- sirable range, the inclusion of the supplement in the diet reduced the total cholesterol concentrations by 10% and LDL-C by 14%, both of which have been associated with a lower risk for second MI events (4). Reduced ApoB in the S group suggests further beneficial effects in the reduction of CHD risk. ApoB has been reported to be a better index of CVD risk than LDL-C, as ApoB is a marker for all the potential atherogenic particles (34,35). Such reductions have been reported previously with the consumption of higher doses of fish oils (36,37) and similar food supplements (23,24). The amounts of lipid-lowering nutrients Values are means 6 SEM, n ¼ 19 for S or n ¼ 20 for C. *Different from T0, P , 0.05.
supplemented each day were quite low: 1 g of fish oil (0.33 g of EPA 1 DHA) and 5.2 g of oleic acid. Still, the effects observed Plasma lipid and ApoB concentrations in the C and S groups at the beginning of the study (T0) and after 3 (T3), 6 (T6),9 (T9) and 12 (T12) mo of intervention1 1 Values are means 6 SEM, n ¼ 19 for S or n ¼ 20 for C. *Different from T0, P , 0.05. yDifferent from C, P , 0.05.
2 ND, not determined.
were rather remarkable compared with other studies that in- increased production of EPA-derived eicosanoids, which possess volved capsules and/or tablets, but were in agreement with less activity than those derived from AA (39).
previous studies using this supplement (21–24) and could be At the present time, proven therapies to reduce hs-CRP levels attributed to the method of administration. Previous short-term include weight reduction (40) and, particularly, statin therapy studies using this food supplement (22) or a similar one (20,24) (41,42). However, in our study, we found reductions of hs-CRP demonstrated a comparable lipid-lowering effect on TC and to be independent of those. A recent report showed that exercise LDL-C, but, in contrast to those reports, our work did not find training and a Mediterranean dietary pattern during phase II of any effect on TG concentrations. A plausible explanation could CR produced a 41% median reduction of hs-CRP that was also be that, in those studies, TG concentrations were above normal independent of statin therapy and weight variation (43). The at baseline, whereas, in our study, TG concentrations were reductions of hs-CRP in the S group of our study agree with that normal (,1.7 mmol/L) (25). Indeed, in 2 other of our interven- report, and both were of similar or greater magnitude to those tion studies with this food supplement, subjects with normal TG observed in numerous studies using statin therapy, with reduc- at baseline did not have TG reductions (21,23). These results tions in hs-CRP between 15 and 20% (41,42). Whereas statin suggest that the supplemented nutrients might contribute to therapy constitutes the major treatment option available for blood-lipid stabilization in the context of a blood-lipid imbal- the reduction of hs-CRP and LDL-C (44), the combination of the supplemented beverage and statins are likely to produce Local production of proinflammatory cytokines in the further CV benefits and deserves to be explored. The CRP reduc- atheromatous plaque increases systemic markers of inflamma- tion observed with the administering of low amounts of anti- tion such as hs-CRP (38). In the present study, the hs-CRP inflammatory nutrients could be attributed, again, to the increased reductions in the S group suggest a reduced risk of further bioavailability of the nutrients through the dairy product and coronary events by amelioration of the inflammatory status. In perhaps to a pleiotropic effect of such nutrients combined.
addition, the decreases of the AA:EPA ratio and increases of the Finally, at the end of the study, the S group of patients had plasma EPA and DHA concentrations in the S group suggest a improved vitamin status, increasing their vitamin E:TC ratio to less proinflammatory and thrombotic environment due to the optimal values (.5.2 mmol/L) (45) and changing their serum Plasma vitamins, tHcy, and CRP concentrations in the C and S groups at the beginning of the study (T0) and after3 (T3), 6 (T6), 9 (T9), and 12 (T12) mo of intervention1 1 Data are presented as means 6 SEM, n ¼ 19 for S or n ¼ 20 for C. *Different from T0, P , 0.05. yDifferent from C, P , 0.05.
2 ND, not determined.
folate concentrations from suboptimal levels at T0 (,15 nmol/L) 10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.
Inflammation, aspirin and the risk of cardiovascular disease in appar- response was observed for plasma vitamin B-6 and RBC folate ently healthy men. N Engl J Med. 1997;336:973–9.
concentrations, even when the amounts administered were only 11. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long- term 70% of the RDAs (17). Taken together, the absorbtion of these mortality in unstable coronary disease. FRISC Study Group. Fragmin supplemented nutrients into plasma might contribute to im- during Instability in Coronary Artery Disease. N Engl J Med. 2000; proved antioxidant defenses (45) and reduced Hcy levels (16).
Both factors are associated with a lower CHD risk because they 12. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam reduce Hcy levels. However, the mean plasma tHcy concentra- PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibreintakes in death and myocardial infarction: DIET and reinfarction trial tions of the patients were within normal range, and the reductions found may be of little clinical importance.
13. Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, Although adult treatment Panel III recommendations em- Djordjevic BS, Dontas AS, Fidanza F, et al. The diet and 17-year death phasize lifestyle and dietary changes in secondary prevention, rate in the Seven Countries Study. Am J Epidemiol. 1986;124:903–15.
recent reports suggest that, because CR programs are poorly 14. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, followed, more attention needs to be paid to dietary approaches Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid- in the management of MI patients after hospital discharge. In the rich diet in secondary prevention of coronary heart disease. Lancet.
1994;343:1454–9.
U.S. only 10–20% of patients participate in CR programs (3); in 15. Kris-Etherton PM, Harris WS, Appel LJ. AHA Nutrition Committee.
the U.K., 10–23% (2); and in Spain, 2% (19).
American Heart Association. Omega-3 fatty acids and cardiovascular The optimal diet for long-term prevention of CHD remains disease: new recommendations from the American Heart Association.
an issue under investigation. Although numerous studies have Arterioscler Thromb Vasc Biol. 2003;23:151–2.
been carried out using the nutrients used in the supplement, to 16. Bronstrup A, Hages M, Prinz-Langenohl R, Pietrzik K. Effects of folic the best of our knowledge, no dietary intervention using a acid and combinations of folic acid and vitamin B-12 on plasma combination of them has been reported in MI patients. This homocysteine concentrations in healthy young women. Am J Clin Nutr.
1998;68:1104–10.
study indicates that therapeutic lifestyle changes, effected 17. Expert group on vitamins and minerals (EVM). Safe upper levels for through a CR program comprised of regular exercise and the vitamins and minerals: report of the expert group on vitamins and intake of low amounts of a combination of healthy nutrients minerals. London (UK): Food Standards Agency; 2003.
(EPA, DHA, oleic acid, folic acid, vitamin B-6, and vitamin E) 18. WHO Study Group. Diet, nutrition and prevention of chronic diseases.
are able to reduce a variety of risk factors in MI patients, and Technical Report Series, No. 916. Geneva (Switzerland), World Health supports the rationale for the use of nutritional programs in the 19. Plaza-Pe´rez I. Estado actual de los programas de prevencio´n secundaria y rehabilitacio´n cardı´aca en Espan˜a. Rev Esp Cardiol. 2003;56:757–60.
20. Visioli F, Rise P, Plasmati E, Pazzucconi F, Sirtori C, Galli C. Very low intakes of n-3 fatty acids incorporated into bovine milk reduce plasma triacylglycerols and increase HDL-cholesterol concentrations in healthy The authors wish to thank S. J. Castro and V. Lozano for help subjects. Pharmacol Res. 2000;41:571–6.
with the patients and data recruitment, C. Rodriguez and A.D.
21. Baro L, Fonolla J, Pena JL, Martinez-Ferez A, Lucena A, Jimenez J, Valero for valuable technical assistance, A. Zafra for help with Boza JJ, Lopez-Huertas E. n-3 Fatty acids plus oleic acid and vitamin the HPLC analysis, and L. Baro´ for helpful discussions.
supplemented milk consumption reduces total and LDL cholesterol,homocysteine and levels of endothelial adhesion molecules in healthyhumans. Clin Nutr. 2003;22:175–82.
22. Carrero JJ, Baro L, Fonolla J, Gonzalez-Santiago M, Martinez-Ferez A, Castillo R, Jimenez J, Boza JJ, Lopez-Huertas E. Cardiovascular effects World Health Organization. The World Health Report: 2004: changing of milk enriched with omega-3 polyunsaturated fatty acids, oleic acid, history. Geneva (Switzerland): WHO; 2004.
folic acid, and vitamins E and B6 in volunteers with mild hyperlipide-mia. Nutrition. 2004;20:521–7.
Dalal H, Evans PH, Campbell JL. Recent developments in secondaryprevention and cardiac rehabilitation after acute myocardial infarction.
23. Carrero JJ, Lo´pez-Huertas E, Salmero´n LM, Baro´ L, Ros E. Daily supplementation with n-3 LC-PUFAs, oleic acid, folic acid and vitamins Ades PA. Cardiac rehabilitation and secondary prevention of coronary B6 and E improves pain-free walking distance and risk factors in heart disease. N Engl J Med. 2001;345:892–902.
peripheral vascular disease patients. J Nutr. 2005;135:1393–9.
Third Report of the National Cholesterol Education Program Expert 24. Benito P, Caballero J, Moreno J, Gutie´rrez-Alca´ntara C, Mun˜oz C, Rojo Panel. Detection, evaluation and treatment of high blood cholesterol in G, Garcı´a S, Soriguer FC. Effects of milk enriched with v-3 fatty acid, adults (ATP III). 2002; National Institutes of Health (NIH), publication oleic acid and folic acid in patients with metabolic syndrome. Clin Nutr.
Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, 25. Velasco JA, Cosin J, Maroto JN, Mun˜iz J, Casasnovas JA, Plaza I, Kannel WB. Prediction of coronary heart disease using risk factors Abadal LT. Guı´as de pra´ctica clı´nica de la Sociedad Espan˜ola de categories. Circulation. 1998;97:1837–47.
Cardiologı´a en prevencio´n cardiovascular y rehabilitacio´n cardı´aca. RevEsp Cardiol. 2000;53:1095–120.
Stamler J, Wentworth D, Neaton JD. Is relationship between serumcholesterol and risk of premature death from coronary heart disease 26. Mataix J, Man˜as M., eds. Tabla de composicio´n de alimentos espan˜oles.
continuous and graded? Findings in 356 222 primary screenes of the 3rd edition. Granada (Spain): Universidad de Granada, 1998.
Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256: 27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concen- tration of low density lipoprotein cholesterol in plasma without use of Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
after myocardial infarction. N Engl J Med. 1990;323:1112–9.
28. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic one-step reaction. J Lipid Res. 1986;27:114–20.
factor after myocardial infarction: the Framingham Study. Ann Intern 29. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and detection. J Chromatogr. 1987;422:43–52.
other markers of inflammation in the prediction of cardiovascular 30. Thurnham DI, Smith E, Flora PS. Concurrent liquid-chromatographic as- disease in women. N Engl J Med. 2000;342:836–43.
say of retinol, alpha tocopherol, beta-carotene, alpha-carotene, lycopene and beta-cryptoxanthin in plasma with tocopherol acetate as Internal 38. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; Standard. Clin Chem. 1988;34:377–81.
31. Fukunaga K, Yoshida M, Nakazono N. A simple, rapid, highly sensitive 39. Calder PC. n-3 Fatty acids and cardiovascular disease: evidence and reproducible quantification method for plasma malondialdehyde by explained and mechanisms explored. Clin Sci (Lond). 2004;107: high-performance liquid chromatography. Biomed Chromatogr. 1998; 40. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss 32. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset reduced C-reactive protein levels in obese postmenopausal women.
SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–6.
41. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, 33. Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters coronary events after myocardial infarction in patients with average co-ingested with a high-fat meal. Biochem Biophys Res Commun.
cholesterol levels. Cholesterol and Recurrent Events (CARE) Investiga- tors. Circulation. 1998;98:839–44.
34. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and 42. Albert MA, Danielson E, Rifai N, Ridker PM, Investigators PRINCE.
apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106:2526–9.
Effect of statin therapy on C-reactive protein levels: the pravastatininflammation/CRP evaluation (PRINCE): a randomized trial and cohort 35. Sniderman A. How, when and why to use apolipoprotein B in clinical practice. Am J Cardiol. 2002;90:S48–54.
43. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein 36. Chan DC, Watts GF, Mori TA, Barrett PH, Redgrave TG, Beilin LJ.
Randomized controlled trial of the effect of n-3 fatty acid supplemen- through cardiac rehabilitation and exercise training. J Am Coll Cardiol.
tation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr. 2003;77:300–7.
44. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized 37. Ouguerram K, Maugeais C, Gardette J, Magot T, Krempf M. Effect of type of immunomodulator. Nat Med. 2000;6:1399–402.
n-3 fatty acids on metabolism of apoB100-containing lipoprotein in 45. Morrissey PA, Sheehy PJ. Optimal nutrition: vitamin E. Proc Nutr Soc.
type 2 diabetic subjects. Br J Nutr. 2006;96:100–6.

Source: http://www.puleva.es/pf/profesionales/estudios_clinicos/pdf/ejerciciofisicoydieta.pdf

Prohibited substances&methods 2002_1.pdf

PROHIBITED CLASSES OF SUBSTANCES AND PROHIBITED METHODS (art. 5 of the Antidoping Examination Regulations/ Adopted by the UCI President on the proposal of the Antidoping Commission of the UCI. UCI List No.01/2002 Entry into effect: 1stMay 2002 2002 PROHIBITED CLASSES OF SUBSTANCES 1. Androgenic anabolising steroids 2. Non-steroidal anabolic agents Peptide hormones, mimetics

Met.final.doc

Pharmacokinetics and Relative Bioavailability of Metformin Hydrochloric Acid Sustained Release Tablet in Healthy Volunteers Yi n X i a o - X i n g , Z h a n g Yi - D i , Z h u o H a i - To n g , S h e n J i a n - P i n g , L i L i - M i n , Q i u J u n . ( I n s t i t u t e o f C l i n i c a l P h a r m a c o l o g y, N a n j i n g M e d i c a l U n i v e r s i t y, N a n j i n g 2 1

Copyright © 2018 Medical Abstracts